Equillium, a clinical-stage biotechnology company, completed the acquisition of Bioniz Therapeutics, a privately held clinical-stage biotechnology company, for $350m. “We were most impressed with Equillium’s synergistic mission, deep expertise in immunology and inflammation and strong development capabilities that are uniquely positioned to carry Bioniz’s assets forward. We have every confidence in the Equillium team to drive these programs to success, and to fully realize the potential of our pipeline and novel product discovery platform,” David Pyott, Bioniz Chairman of the Board.